61 - Comparable Efficacy of Once-Weekly Subcutaneous Semaglutide in Subjects With Type 2 Diabetes Aged <65 and ≥65 Years: SUSTAIN 1–5 and 7–10 Posthoc Analysis

In the phase 3 SUSTAIN clinical trial program, once-weekly semaglutide was more effective than comparators at lowering HbA1c and body weight in subjects with type 2 diabetes (T2D). This posthoc analysis of SUSTAIN 1–5 and 7–10 compared efficacy of semaglutide in subjects <65 years (nonelderly) with those ≥65 years (elderly) vs placebo and active comparators. These comparisons were reported individually, by trial.